Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Dear Isis
Supporters and Shareholders,
I would like to start by thanking you for your continuing
support of Isis. We believe we are at one of the most successful
moments in our history. We are truly at the end of the beginning of
creating a unique company with a novel drug discovery platform,
which we believe addresses many of the issues haunting the
pharmaceutical industry.
Our progress is predicated largely upon the success of our
flagship drug, mipomersen. Mipomersen continues to perform well and
progress toward commercialization. Isis, our investigators and
members of the medical community are very encouraged by the results
that were presented at the AHA last week. To get a sense of their
support of the drug, I would encourage you to listen to the replay
of the mipomersen investigator panel presentation that was
conducted during AHA last week. I think you will hear not only
their enthusiasm for the drug but their hope that mipomersen will
provide a new treatment alternative for their patients at very high
risk of cardiovascular disease.
We are disappointed with the reaction on Wall Street to what we
believe is very positive news. We believe mipomersen will continue
to provide results that speak for themselves. Each success brings
us closer to getting mipomersen to the market and making the drug
available to patients in need.
Our antisense technology provides a direct route from genes to
drugs with the opportunity to dramatically improve the productivity
of the pharmaceutical industry. With 19 drugs in development, we
have one of the largest and most diverse pipelines in our industry.
We know that sick people depend on us. We continue to strive for
excellence as we create drugs for the future. We also recognize
that behind our successes is the support we receive from you. I
would like to personally thank you for that.
Sincerely, Stanley T. Crooke Isis Chairman and Chief Executive Officer
Source: Isis Pharmaceuticals, Inc.
CONTACT: Kristina Lemonidis (Investors), +1-760-603-2490, or
Amy
Blackley, Ph.D. (Media), +1-760-603-2772, both of Isis
Pharmaceuticals, Inc.
Web Site: http://www.isispharm.com
Posted: November 2009
